

Date: 04.08.2016

To,
Department of Corporate Service (DCS-CRD),
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400001

Sub: Submission of un-audited Financial Results for quarter ended 30th June, 2016 in pursuance of regulation 33 of Listing Obligation and Disclosure Requirement, 2015 along with Limited Review Report

Ref.: NGL Fine Chem Limited, Script Code- 524774

Dear Sir,



Kindly find enclosed herewith duly approved un-audited Financial Results pursuant to regulation 33 of Listing Obligation and Disclosure Requirement, 2015, for the quarter ended 30th June, 2016

Kindly take on record and acknowledge receipt of the same.

Thanking You,

Yours faithfully,

For NGL FINE CHEM LIMITED



**RAHUL NACHANE
MANAGING DIRECTOR**

DIN: 00223346

Encl: As above

NGL FINE-CHEM LIMITED

Regd Office: 301, E-Square
Subhash Road, Vile Parle (E), Mumbai-400057

CIN: L24110MH1981PLC025884



UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2016

PART I		Quarter ended			Year ended
		30.06.2016 (Unaudited)	31.03.2016 (Audited)	30.06.2015 (Unaudited)	31.03.2016 (Audited)
Rupees in lakhs					
1	a. Net Sales / Income from Operations	2,472.78	2,563.75	2,411.16	9,484.00
	b. Other Operating Income	55.38	34.36	53.84	145.25
	Total Income	2,528.16	2,598.11	2,465.00	9,629.25
2	Total Expenditure :				
	a. Consumption of Raw Material	963.55	893.05	1,075.48	3,909.45
	b. (Increase)/Decrease in stock in trade and work in progress	1.99	175.53	25.26	172.28
	c. Employees Cost	318.83	285.06	278.76	1,134.62
	d. Depreciation	74.22	77.03	64.02	272.24
	e. Other Expenditure	543.80	590.09	557.42	2,256.56
	g. Total	1,902.39	2,020.76	2,000.94	7,745.15
3	Profit from operations before other income, finance costs (1 - 2)	625.77	577.35	464.06	1,884.10
4	Other Income	3.76	10.56	2.52	20.03
5	Profit from ordinary activities before finance costs (3 + 4)	629.53	587.91	466.58	1,904.13
6	Finance Costs	(22.27)	(39.29)	(30.67)	(117.32)
7	Profit from ordinary activities before tax (5 - 6)	607.26	548.62	435.91	1,786.81
8	Exceptional Items	-	-	-	-
9	Net Profit for the Period (7 - 8)	607.26	548.62	435.91	1,786.81
10	Tax Expense	(214.02)	(199.04)	(158.39)	(646.99)
11	Net Profit (9 - 10)	393.24	349.58	277.52	1139.82
12	Extra ordinary item (net of tax expenses)	-	-	-	-
13	Net Profit/Loss for the period (11-12)	393.24	349.58	277.52	1,139.82
14	Share of Profit / Loss of associates	-	-	-	-
15	Minority Interest	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit/loss of associates (13-14-15)	393.24	349.58	277.52	1,139.82
17	Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each)	308.90	308.90	308.90	308.90
18	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	N.A.	N.A.	N.A.	N.A.
19	Earnings Per Share (EPS)				
	a) Basic	6.37	5.66	4.49	18.45
	b) Diluted	6.37	5.66	4.49	18.45
PART II					
A	Particulars of Shareholding				
1	Public Shareholding				
	- Number of Shares	2,094,802	2,094,802	2,189,837	2,094,802
	- Percentage of Shareholding	33.91%	33.91%	35.45%	33.91%
2	Promoters and promoter group shareholding				
	a) Pledged / Encumbered				
	- Number of Shares	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.00%	0.00%	0.00%	0.00%
	- Percentage of shares (as a % of the total share capital of the company)	0.00%	0.00%	0.00%	0.00%
	b) Non-encumbered				
	- Number of Shares	4,083,222	4,083,222	3,988,187	4,083,222
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the company)	66.09%	66.09%	64.55%	66.09%

- The above results were reviewed by the Audit Committee and have been taken on record by the Board of Directors of the Company at their meeting held on August 4, 2015 and has been subjected to Limited Review by the statutory auditors who have issued an unqualified report
- The Company's operations consist only of one segment i.e. pharmaceuticals, hence Segment Reporting required under AS17 is not applicable.
- The figures of the corresponding period have been regrouped wherever necessary.

Mumbai
04-Aug-16

For and On behalf of Board of Directors,

Rahul Nachane
Rahul Nachane
Managing Director

